Moteur de recherche d’entreprises européennes
Financement de l’UE (4 058 815 €) : SuperCol : Conception rationnelle de particules colloïdales super-sélectives et réactives pour des applications biomédicales Hor16/09/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
SuperCol : Conception rationnelle de particules colloïdales super-sélectives et réactives pour des applications biomédicales
SuperCol will train a new generation of scientists in modern super-resolution microscopy and particle functionalisation for improved colloidal design and nanoscale interfacial control for particle-based biosensing. Colloidal-particle-based materials have shown unique abilities in (bio)sensing and other applications because of their large surface-to-volume ratio and biochemical functionalisation. However, we have had only limited success in controlling the sensing properties and cannot yet realise the sensitivity, selectivity and kinetic control that is achieved by e.g. cellular sensing networks. In order to realise this we need to initiate a paradigm shift and create surfaces with a quantified and rationally designed number, distribution, and activity of receptors. To achieve this, we need to understand the structure-function relation between the loading patterns and the sensing characteristics. At this moment, we do not know: (1) how to accurately visualise individual receptors on colloidal surfaces, (2) how to influence the number, distribution and activity of receptors and (3) how this surface organisation translates to highly desired functionalities such as responsiveness and super-selectivity. Super-resolution imaging, advanced particle surface chemistry and advanced modelling will allow to bridge these gaps. However, the field lacks the human capital that can oversee and bridge these disciplines to advance these approaches and effectively (a) control, (b) visualise and quantify, and (c) rationally design surface-functionality to advance particle-based biomedical applications. SuperCol will train the next generation of researchers to overcome this barrier, and will develop e.g. super-selective biosensors for dengue and cholera, and responsive particles that allow biomolecules to be captured (e.g. inflammation markers) and released (e.g. doxorubicin) on demand.
| Blusense Diagnostics ApS | 297 522 € |
| Danmarks Tekniske Universitet | 595 044 € |
| HIQ-Nano Srl | 261 500 € |
| Katholieke Universiteit Leuven | 512 640 € |
| MAX-Planck-Gesellschaft ZUR Forderung DER Wissenschaften e. V. | 505 577 € |
| Technische Universiteit Eindhoven | 1 062 480 € |
| Universita Degli Studi Di Roma LA Sapienza | 261 500 € |
| Universite DE Fribourg | 562 553 € |
https://cordis.europa.eu/project/id/860914
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.